Ignite Creation Date:
2024-05-05 @ 10:17 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01071655
Status:
COMPLETED
Last Update Posted:
2015-03-24
First Post:
2010-02-15
Brief Title:
Selecting Treatment in Colorectal CancerCapecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer
Sponsor:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Organization:
Spanish Cooperative Group for the Treatment of Digestive Tumours TTD
Study Overview
Official Title:
Selecting Treatment in Colorectal Cancer Capecitabine or 5-fluorouracil Selection According to Polymorphisms in TS-3UTR and ERCC1-118 to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SETICC
Brief Summary:
The purpose of the study is to evaluate the efficacy and safety of the capecitabine or 5-fluorouracil selection according to polymorphisms in TS-3UTR and ERCC1-118 to be combined with oxaliplatin or irinotecan as first-line chemotherapy in advanced colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-012562-31 | EUDRACT_NUMBER | None | None |